Evidence map›Paper›PMID 38305785›Full record

ArticleActa crystallographica. Section F, Structural biology communications2024

Crystal structure and biophysical characterization of IspD from Burkholderia thailandensis and Mycobacterium paratuberculosis.

Phillip G Pierce, Brian E Hartnett, Tosha M Laughlin, Joy M Blain, Stephen J Mayclin, Madison J Bolejack, Janette B Myers, Tate W Higgins, David M Dranow, Amy Sullivan and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta crystallographica. Section F, Structural biology communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Phillip G PierceSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA.ORCID 0000-0002-8176-770X
Brian E HartnettDepartment of Chemistry and Biochemistry, Northern Illinois University, 1425 Lincoln Highway, DeKalb, IL 60115, USA.
Tosha M LaughlinDepartment of Chemistry and Biochemistry, Northern Illinois University, 1425 Lincoln Highway, DeKalb, IL 60115, USA.
Joy M BlainDepartment of Chemistry and Biochemistry, Northern Illinois University, 1425 Lincoln Highway, DeKalb, IL 60115, USA.
Stephen J MayclinUCB Pharma, 7869 NE Day Road West, Bainbridge Island, WA 98110, USA.ORCID 0000-0002-1600-4554
Madison J BolejackUCB Pharma, 7869 NE Day Road West, Bainbridge Island, WA 98110, USA.
Janette B MyersSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA.ORCID 0000-0002-7758-2649
Tate W HigginsSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA.ORCID 0000-0001-6889-6331
David M DranowUCB Pharma, 7869 NE Day Road West, Bainbridge Island, WA 98110, USA.ORCID 0000-0003-1871-2455
Amy SullivanSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA.
Donald D LorimerUCB Pharma, 7869 NE Day Road West, Bainbridge Island, WA 98110, USA.ORCID 0000-0002-9638-8083
Thomas E EdwardsUCB Pharma, 7869 NE Day Road West, Bainbridge Island, WA 98110, USA.ORCID 0000-0002-0474-8003
Timothy J HagenDepartment of Chemistry and Biochemistry, Northern Illinois University, 1425 Lincoln Highway, DeKalb, IL 60115, USA.ORCID 0000-0003-1929-9121
James R HornDepartment of Chemistry and Biochemistry, Northern Illinois University, 1425 Lincoln Highway, DeKalb, IL 60115, USA.ORCID 0000-0002-5694-0232
Peter J MylerSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA.ORCID 0000-0002-0056-0513
Center for Infectious Disease Research · USNorthern Illinois University · US

Funding

Design and Study of IspF Inhibitors as Antibacterial AgentsR15AI113653 · NIAID · NORTHERN ILLINOIS UNIVERSITY · PI HAGEN, TIMOTHY JOSEPH · 2014 to 2014
$356k
NIAID NIH HHS HHSN272201200025CNIAID NIH HHS HHSN272201700059CNIAID NIH HHS R15 AI113653NIH HHS 1R15AI113653-01
6 · The paper itself

Abstract

The methylerythritol phosphate (MEP) pathway is a metabolic pathway that produces the isoprenoids isopentyl pyrophosphate and dimethylallyl pyrophosphate. Notably, the MEP pathway is present in bacteria and not in mammals, which makes the enzymes of the MEP pathway attractive targets for discovering new anti-infective agents due to the reduced chances of off-target interactions leading to side effects. There are seven enzymes in the MEP pathway, the third of which is IspD. Two crystal structures of Burkholderia thailandensis IspD (BtIspD) were determined: an apo structure and that of a complex with cytidine triphosphate (CTP). Comparison of the CTP-bound BtIspD structure with the apo structure revealed that CTP binding stabilizes the loop composed of residues 13-19. The apo structure of Mycobacterium paratuberculosis IspD (MpIspD) is also reported. The melting temperatures of MpIspD and BtIspD were evaluated by circular dichroism. The moderate T

Indexed as

BurkholderiaMycobacterium avium subsp. paratuberculosisCrystallography, X-RayDiphosphatesDiphosphatesBurkholderia thailandensiscytidylyltransferasesIspDMycobacterium paratuberculosisSeattle Structural Genomics Center for Infectious DiseaseSSGCIDstructural genomicstransferases

Identifiers

PMID38305785
PMCPMC10836425
OpenAlexW4391431272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.